Blood test for tumor DNA in early triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a new, untreated early-stage triple-negative breast cancer (tumor ≤2 cm, no spread to lymph nodes or other organs).
- Your cancer is grade 2 or 3 and your ER and HER2 tests show it is triple-negative.
- You are able to have chemotherapy and surgery, and you have not had chemotherapy before.
- You agree to give blood samples for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
This study uses a simple blood test (liquid biopsy) along with imaging scans to look for early signs that triple-negative breast cancer may have returned in patients who still had cancer after chemo. It aims to catch a possible recurrence sooner, which could help guide earlier treatment.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests whether using blood tests and imaging during chemotherapy and immunotherapy can help guide treatment for early-stage triple-negative breast cancer. It aims to improve outcomes by adjusting treatment based on how the cancer responds.
This study tests whether a new approach using a genetic test can guide treatment for low-risk triple-negative breast cancer. It aims to help patients avoid unnecessary chemotherapy while keeping the cancer from coming back.
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.